IntroDuctIon
The study of lymphangiogenesis is an emerging research field that is involved in understanding the fundamental mechanisms of lymphatic vessel growth and function under physiological and pathological conditions 1, 2 . Particularly, intra-and peritumoral lymphangiogenesis have been associated with cancer metastasis, and inhibition of lymphangiogenesis might potentially offer a new opportunity for the treatment of cancer metastasis 1 . In addition, dysfunction of lymphatic vessels often leads to primary and secondary lymphedema, which markedly impairs the function of affected tissues or organs. Thus, delivery of lymphangiogenic factors to these affected tissues or organs might restore their functions by establishing functional lymphatic networks 3 . Similar to hemangiogenesis, the formation of new lymphatic networks is a multistep process that involves lymphatic endothelial cell (LEC) proliferation, migration, tube formation, maturation and remodeling, all of which are tightly regulated by lymphangiogenic factors and inhibitors [4] [5] [6] [7] [8] [9] [10] [11] . Lymphatic vessel growth may represent the imbalanced consequence of positive and negative regulators tipping toward positive regulation. Although there are several in vitro and semi-in vivo assays to study LEC proliferation, migration and tube formation [12] [13] [14] , these assays do not usually recapitulate the lymphangiogenic process in vivo in a functional lymphatic network. In addition, in vitro assays do not address issues of lymphatic vessel stability and remodeling, which are essential for the maintenance of lymphatic functions. For these reasons, a reliable and powerful in vivo lymphangiogenesis assay should be developed.
Unlike blood vessels, lymphatic vessels are not perfused with blood cells and thus remain invisible in a given tissue or organ. Detection of lymphatic vessels is usually achieved by drainage of dyes such as Evan's blue or India ink, which are collected from the extravascular space 15 . Alternatively, immunohistochemical staining of tissues with lymphatic-specific markers such as lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), podoplanin or vascular endothelial growth factor receptor 3 (VEGFR3) provides an opportunity to study the fine structure of lymphatic microvessels 9, 16 . However, these methods generally do not allow distinction between pre-existing lymphatics and the newly formed lymphatic vessels.
We have developed a quantitative lymphangiogenesis model in the mouse cornea to study the process of lymphatic vessel growth [4] [5] [6] [7] [8] [9] 11 . This model is similar to a corneal angiogenesis model 6, 17, 18 . As the corneal tissue remains avascular for both blood and lymphatic vessels, all lymphatic vessels are newly formed. Thus, in comparison with other in vivo lymphangiogenesis models, the corneal model offers a unique opportunity to study lymphatic vascular formation, structure, stability and remodeling. The avascular feature of the corneal tissue makes this model useful for a quantitative assessment of the lymphangiogenic effect of a given factor. Using this model, we and others have studied the effects of various growth factors on lymphangiogenesis and lymphatic vessel function [4] [5] [6] [7] [8] [9] 11, 19 . Others have studied inflammation-induced lymphangiogenesis in the mouse cornea, in which suturing a thread in the epithelial layer induces a robust inflammatory response 20 . Although this inflammation-induced corneal lymphangiogenesis model allows investigation of lymphatic vessel growth, this method uses different principles than those used in our current protocol. First, the corneal suturing assay is not a reliable quantitative assay because the sizes of the suture thread are not uniform, leading to variation among inflammatory responses in different corneas. Second, inflammation-induced lymphangiogenesis can be mediated by a variety of immunological cytokines and growth factors, which can be present in different amounts and ratios. These variations make it difficult to test an antagonist or inhibitor targeting a specific growth factor or cytokine because its identity and amount may remain unidentified. Third, inflammation is known to potently induce blood vessel angiogenesis in the cornea. Therefore, it would be difficult to study the putative lymphangiogenic effect of a given factor or cytokine. Finally, in the inflammation-induced corneal model, it is difficult to study the synergistic lymphangiogenic activity between two or more lymphangiogenic factors. However, inflammation occurs in most pathological conditions, including cancer and chronic inflammatory diseases. Therefore, the inflammation-induced corneal lymphangiogenesis can be used for testing the effect of drugs on lymphangiogenesis without targeting a specific factor. In this aspect, the corneal suturing assay may be valuable for screening inhibitors that block a common pathway of lymphangiogenesis. In contrast to the inflammation-induced corneal lymphangiogenesis model, implantation of a polymer-based micropellet containing a single factor (or a combination of two or more factors) would not usually induce inflammatory responses unless the factor introduced is a potent inflammatory cytokine. In support of this view, implantation of a micropellet without lymphangiogenic factors does not elicit lymphangiogenic response. In addition, the present protocol describes a method in which the amount of lymphangiogenic factor, the size of the micropellet, the implantation site and the time point of responses are all well defined, thus allowing an investigator to quantitatively study the lymphangiogenic activity of any given factor in this model. Another advantage of our protocol is that the corneal lymphangiogenesis model enables the investigation of the inhibition of specific growth factor-induced lymphangiogenesis by any known or unknown protein or chemical compound. For example, our model allows investigators to study whether fibroblast growth factor-2(FGF)-2-induced lymphangiogenesis can be inhibited by an anti-VEGFR3 neutralizing antibody 7, 8 . Thus, this assay could be used for therapeutic assessment of anti-lymphangiogenic compounds for drug development; it is also complementary to other lymphangiogenesis models 21 , thereby allowing the investigation of structural and functional aspects of lymphatic vessels under a variety of physiological and pathological settings.
Mouse corneal lymphangiogenesis model

Advantages and limitations Key advantages:
The main advantage of this corneal lymphangiogenesis model is that it allows the study of lymphatic vessel formation in an avascular tissue, thus avoiding any pre-existing vascular background. The avascular nature of the corneal tissue also allows investigation of lymphatic vessel formation in relation to blood vessel growth. Lymphangiogenic stimulus-induced newly formed lymphatic vessels can be accurately quantified. The corneal assay can be performed in all strains of mice, including genetically modified mice such as transgenic and knockout lines. Implantation of a combination of several molecules into the corneal micropocket allows investigation of the joint effect of various factors on lymphangiogenesis. In the absence of pre-existing lymphatics, the structure and architecture of lymphatic vessels induced by various factors can be studied and compared. Anti-lymphangiogenic activity of a small chemical compound, nucleotide or protein molecule can be studied by co-implantation 
Limitations:
Creation of a micropocket in the mouse cornea demands highly skillful micro-operations under a stereomicroscope. Owing to technical demands, a limited number of corneas can be operated on in each experiment. Owing to defective phenotypes of genetically manipulated mice, implantation of lymphangiogenic factors should be performed in newborn mice prior to lethality 22, 23 . Implantation of lymphangiogenic factors in newborn corneas is technically difficult and challenging.
Experimental design Preparation of micropellets.
To ensure the success and reproducibility of experiments, uniform micropellets should be prepared in such a way that each micropellet contains an equal amount of a lymphangiogenic stimulus. For this reason, we use nylon mesh (300 µm) as a pellet mode (Fig. 1) . Lymphangiogenic factors should be thoroughly mixed with sucralfate (heparin-binding slow-release substance) and hydron in 99.5% (vol/vol) ethanol prior to imbedding into the grids of a nylon mesh. The growth factor-containing slow-release paste is evenly spread on the nylon mesh by smearing the substance using a spatula. The nylon mesh embedded with lymphangiogenic factors should be dried for at least 1 h at room temperature (23-25 °C) . The embedded pellets are released by carefully tearing each nylon string with a pair of forceps. Dried and uniformed micropellets can be stored at −20 °C for at least 1 year (see PROCEDURE Steps 1-5 for preparation of micropellets).
When lymphangiogenic factors are stored by freezing, it is important to place them in small aliquots and avoid the repeated freeze-thaw cycles. Ideally, an in vitro cell-based activity assay, such as cell proliferation or migration assay 5 , should be established in parallel to monitor the biological activity of each batch of the commercialized or homemade lymphangiogenic factors. During preparation of lymphangiogenic factors, it is recommended that these factors be suspended in a low-salt solvent to avoid corneal irritation.
Corneal implantation and controls. As surgical operation in the mouse cornea can produce traumatic pain for animals, we highly recommend that creation of a micropocket be performed only on one eye of each animal (Fig. 1) . Surgical operations should not be performed until the animals are deeply anesthetized. To obtain statistically meaningful results, we typically use 7-10 animals in each experimental group; at least two independent experiments should be performed in order to obtain reproducible results. Positive and negative controls should be included in each experiment. VEGF-C, a known potent lymphangiogenic factor, is typically used as a positive control in our experimental settings. For negative controls, it is recommended to use the same slow-release polymer without factors or with a carrier protein such as albumin. If antibodies or chemical compounds are used as inhibitors, a buffer-treated or an irrelevant antibody/compound-treated group should be used as controls. In addition to substance controls, it is critical that the animals of the same strain, age and sex be chosen in the control groups as these parameters can affect angiogenic responses 24 . If one eye is chosen for surgical operation in each animal, it is preferable to choose the eye of the same side in other animals.
Immunohistochemistry and data analysis. Unlike blood vessels, lymphatic vessels are not perfused with red blood cells and remain invisible under light microscopy. However, we highly recommend photographing the cornea if the implanted factor induces hemangiogenesis. These data are extremely useful in cases when researchers plan to study the relation between hemangiogenesis and lymphangiogenesis. After careful dissection, the entire corneal tissue should be used for whole-mount staining with lymphatic-specific markers such as LYVE-1. We routinely perform double or triple immunostaining using combinations of several antibodies specific for blood and lymphatic vessels. The combinatorial detection setting allows us to study the relationships between blood vessels and lymphatic vessels. However, if several antibodies raised from the same species are used, it may be difficult to perform double or triple immunostaining; thus, selection of antibodies from different species should be considered. The stained corneal tissues should be analyzed using a multichannel confocal microscope that detects positive signals by displaying different colors. It is highly recommended that lymphatic vessels from the entire cornea be used for quantification analysis, and that the average vascular area from 7 to 10 corneas be used to obtain a statistically meaningful calculation. If representative pictures are used for comparative analysis between different groups, they should be chosen from the same 'clock' position of the eye.  crItIcal This compound may not be commercially available from this company. In this case, an equivalent substitute from other companies should be considered. Hypnorm (VetaPharma, cat. no. Vm21757/4000) Methanol (Sigma-Aldrich, cat. no. 32213) ! cautIon Handling of methanol should always be carried out in a chemical fume hood and by wearing protective gloves and safety goggles because it is highly toxic to the nervous system. Mice ! cautIon Animals of the same strain, age and sex are highly recommended unless the experiment is designed to detect the variation of lymphangiogenesis by these parameters. All animal studies must be reviewed and approved by the relevant national and institutional animal care and use committees.
MaterIals
•
• Nonimmune goat serum (Vector Laboratories, cat. no. S-1000) Paraformaldehyde (PFA; Sigma-Aldrich, cat. no. 441244) ! cautIon PFA is highly toxic and is an irritant if exposed to skin, inhaled or swallowed. Working with PFA is always recommended to be done in a chemical fume hood with appropriate protective gloves and safety goggles. In case of spillage, immediate cleaning is required because the precipitated powder can be easily dusted in the air. Freshly prepared PFA can be stored at 4 °C for up to 2 weeks. PBST (0.3%, vol/vol) To prepare 50 ml of PBST (0.3% (vol/vol) Triton X-100 in PBS), add 0.15 ml of Triton X-100 to 49.85 ml of 1× PBS. Vortex the solution for a few seconds. The solution can be stored at room temperature for up to 6 months. Milk blocking buffer (3%, wt/vol) To prepare 100 ml of 3% (wt/vol) milk blocking buffer, add 3 g of dried fat-free skim milk powder to 100 ml PBST. This buffer should always be freshly prepared for each experiment.
•  crItIcal step Do not move the mouse after injection, and carefully observe the depth of anesthesia by monitoring the mouse's respiratory rate. The effects of the anesthesia will last for ~3 h.
8|
After the mouse is fully anesthetized, lay the mouse under the operation microscope with the right eye facing up.  crItIcal step Only operate on one eye per mouse. Prewarm the warming hood to 34 °C before the operation (see Step 9) . ? trouBlesHootInG 9| Operation: Protrude the right eye with the jeweler's forceps.  crItIcal step Gently touch the cornea with the forceps to ensure that the mouse does not have any local or systemic reactions. This step is essential to avoid pain for mice and to ensure smooth surgical operations in the cornea.
? trouBlesHootInG 10| Make an intrastromal linear keratotomy incision with the surgical blade.
? trouBlesHootInG 11| Choose a micropellet site at the anterior position along the 6-h midline, one-third of the distance from the circumferential tip of the eyeball (Fig. 1) . Dissect a micropocket toward the temporal limbus with a modified von Graefe knife.
? trouBlesHootInG 12| Place a micropellet on the corneal surface near the incision site with the jeweler's forceps. Insert the micropellet into the end of the pocket with a tissue needle.  crItIcal step We recommend that experimenters do not drink coffee or other caffeine-containing beverages before operating on corneas, as neuroexciting substances may result in shaky hands and inaccuracy in operation and micropellet insertion. We also suggest that the experimenter should take at least a 5-min break between each operation to relax the vision and to ensure a smooth and skillful operation.
? trouBlesHootInG 13| Post-operative care: Apply erythromycin (an antibiotic ointment) to the operated eye.  crItIcal step If erythromycin is not available, other broad-spectrum antibiotic ointments should be used as substitutes. Ointments without antibiotics are not recommended for use because operation-induced infection could trigger an angiogenic or lymphangiogenic response.
14|
Carefully move the mouse into the warming hood, which has been prewarmed to 34 °C.
15|
Intramuscularly inject 80 µl of 0.3 mg ml − 1 buprenorphine into each mouse 1 h post-operation to relieve pain.
16|
Move the recovered mice from the warming hood at the end of the 2-h operation; move them back into their original cages and place some food in the cage.  crItIcal step It is critical that each mouse be returned to its original cage without changing bedding materials; a new environment may increase post-operative stress for the mice.
17| Repeat
Step 15 on day 1 after the operation and observe the health of the mice. Pay special attention to the operated eyes to ensure that there is no infection or other irritation.
photograph cornea of operated mouse • tIMInG variable; typically 10-15 min per cornea 18| Anesthetize a pellet-implanted mouse on post-operative day 5 or 6; use the anesthesia solution of Hypnorm, Dormicum and dH 2 O (see Step 6) .
19|
Lay the mouse, with the right eye facing up, under the stereomicroscope equipped with a digital camera, which is connected to a laptop computer. Protrude the right eye with fingers and focus on the area around the implanted pellet and capture 5-8 images per eye.  crItIcal step Two people are usually needed to carry out Steps 19-22.
? trouBlesHootInG 20| Localize the mouse head in an appropriate position, allowing full exposure of the entire area around the implanted micropellet. Maneuver the mouse body to enable exposure of the vascularized area of the cornea. Once the correct position is defined, capture a sharp picture using a digital camera connected to a computer.  crItIcal step A cold light source (LQ 1600 from Fiberoptic-Heim) should be used at low magnification (×1.5 magnification). Warm light may damage the cornea and cause pain for mice.
21|
While one person protrudes the right eyeball with fingers and looks at the cornea under the microscope, the other person should capture a picture by focusing on the blood vessels around the micropellet.
22| Capture a few pictures for each micropellet-implanted eye. Always remember to capture images with a ruler under the same magnification as a reference.  crItIcal step It is critically important that corneal neovascularization is captured at a similar position in all experimental mice, directly allowing comparison of corneal angiogenesis induced by different factors in different groups.
Corneas that are implanted with polymer alone should be recorded as negative controls.
cornea whole mount • tIMInG 5 d 23| Collection and fixation of tissues, day 1: Euthanize mice in a carbon dioxide chamber filled with 100% CO 2 for at least 10 min. Ensure that all mice lose consciousness and completely stop breathing. Remove the micropellet-implanted eyeballs from dead mice with a pair of forceps and a pair of scissors.
24|
With spring scissors, dissect the cornea from the rest of the eye tissue under a stereomicroscope.
25|
Fix the corneal tissue with 4% (wt/vol) PFA at 4 °C overnight.  crItIcal step Tissues should always be obtained fresh and fixed immediately in order to obtain reliable staining results.
26| Pretreatment and blocking, day 2: Add 1 ml of 1× PBS into each well of a 12-well plate. Transfer each 4% (wt/vol) PFA-fixed cornea into a well using a spatula. To remove PFA, wash the corneal tissue at least three times with 1× PBS thoroughly for 1 h on a rocking board.  crItIcal step Label each well with a permanent marker on the bottom of the plate. We do not recommend labeling the lid, as confusion may arise by misplacing it on the plate.
27|
Digest the corneal tissue in a new 12-well plate with 1 ml of 20 µg ml − 1 proteinase K solution (dilute in 10 mM Tris-HCl buffer, pH 7.4) per well for 5 min at room temperature.  crItIcal step Before transferring the corneal tissue into a new well, the new plate should be carefully labeled as described in Step 26.
28|
Transfer the corneal tissue into a new 12-well plate containing 1 ml of 100% methanol per well; allow the methanol to penetrate the corneal tissue at room temperature for 30 min in a chemical fume hood.  crItIcal step Before transferring the corneal tissue into a new well, the new plate should be carefully labeled as described in Step 26.
29|
In a new 12-well plate on a rocking board, wash the corneal tissue with 1 ml of 1× PBS per well at least three times at room temperature for 30 min.
30|
Block the corneal tissue in 1 ml of blocking buffer (3% (wt/vol) milk in PBST) per well in a new 12-well plate and incubate at 4 °C overnight on a rocking board.  crItIcal step Before transferring the corneal tissue into a new well, the new plate should be carefully labeled as described in Step 26.
31| Primary antibody staining, day 3:
Prepare primary antibodies in a 1.5-ml Eppendorf tube as follows: rat anti-mouse CD31 monoclonal antibody (dilute 1:200 in PBST), rabbit anti-mouse LYVE-1 antibody (dilute 1:200 in PBST) and goat anti-mouse VEGFR3 antibody (dilute 1:50 in PBST). To minimize the use of an excessive amount of antibodies, add 80 µl of primary antibody solution into each well of a carefully labeled 48-well plate. Transfer the corneal tissue from blocking buffer into the primary antibody solution and incubate for 16 h at 4 °C on a rocking board.  crItIcal step To obtain double or triple staining, primary antibodies that are mentioned above can be combined.
32| Secondary antibody staining, day 4:
Remove the primary antibody solution, and transfer the corneal tissue into a new well of a 12-well plate. On a rocking board, wash the corneal tissue thoroughly with 1 ml of PBST per well at 4 °C for 1.5 h.
33|
Remove PBST and add 1 ml of blocking buffer per well, and incubate at room temperature for 1.5 h on a rocking board.
34|
Prepare secondary antibodies in a 1.5-ml Eppendorf tube as follows: Alexa Fluor 488-conjugated donkey anti-rabbit antibody (dilute 1:200 in blocking buffer) or Cy5-conjugated goat anti-rabbit antibody (dilute 1:200 in blocking buffer), an Alexa Fluor 555-conjugated goat anti-rat antibody (dilute 1:200 in blocking buffer) and/or Cy3-conjugated donkey anti-goat antibody (dilute 1:200 in blocking buffer), and Cy5-conjugated donkey anti-rat (dilute 1:150 in blocking buffer). Add 80 µl of each secondary antibody solution to a new well of a 48-well plate. Remove blocking buffer and transfer the corneal tissue into the secondary antibodies. Incubate at room temperature for 2 h on a rocking board.  crItIcal step To obtain double or triple staining, combinations of secondary antibodies that are mentioned above can be used, depending on the choice of primary antibodies. Procedures involving the handling of secondary antibodies should be carried out under relatively weak light, as strong light may quench the fluorescent signals.
35|
Dilute blocking buffer 1:1 with PBST, and add 1 ml of diluted blocking buffer into each well of a new 12-well plate. Transfer the corneal tissue from the secondary antibody solution into diluted blocking buffer. Wash the cornea thoroughly with the diluted blocking buffer for 1 h at room temperature on a rocking board.
36|
Remove the blocking buffer and wash the corneal tissue with 1 ml PBS per well at 4 °C overnight on a rocking board.
37| Tissue mounting, day 5:
Remove the corneal tissue from PBS and place each cornea on a separate glass slide. Secure the cornea with a pair of forceps in one hand, and make three slits with a scalpel blade (at respective clockwise direction 120°, 240° and 360°) to flatten out the cornea (Fig. 1) . Remove any excess PBS with a piece of clean tissue and add one drop of Vectashield mounting solution on each cornea. Cover the corneal tissue with a cover slide (22 × 22 mm) and seal the slide with colorless nail polish.  pause poInt Slides may be stored for several weeks if they are kept in the dark at − 20 °C with Vectashield, and nail polish may be used to seal coverslips to prevent fluorescence from quenching. However, immediate further analysis usually yields the best results if time allows.  crItIcal step If the stained corneal tissue is stored at − 20 °C, the slides should be kept in a horizontal position because the Vectashield mounting solution can leak out and disrupt further analysis.
Imaging
• tIMInG variable; typically 6-8 h for 10 corneal samples 38| Obtain 3D images of whole-mount stained corneal tissue using a Nikon D-eclipse C1 and EZ-C1 3.90 software (or any other equivalent confocal microscope). Low magnification (×4 objective) is suitable to obtain a phenotypic analysis of lymphatic vessels in the entire cornea. Take serial micrographs at 5-10 µm × 8-10 layers; use Adobe Photoshop to merge them to obtain a composite picture from these partially overlapping low-magnification images. Higher magnifications (×10, ×20 or ×40 objectives) can be used to obtain a detailed analysis, including precise localization, morphology and formation of lymphatic vessels in the cornea. These images can be harvested and further quantitatively analyzed using Adobe Photoshop and Microsoft Excel.
Quantification
• tIMInG variable; typically 10 min for each corneal image 39| To obtain a statistically meaningful quantitative data set, at least 6-8 eyes from each group should be used for quantification analysis. The positive fluorescent signals of lymphatic vessels from the entire cornea (×4 objective) should be deposited in the Adobe Photoshop program (shown as green signals in Fig. 2a) . Use the range tool to select green signals, and use the magnetic lasso tool to define the area of lymphatic vessels (Fig. 2) . The number of pixels can be seen in the histogram window (y-pixels), which can be recorded and analyzed in a Microsoft Excel file (or with a similar program) to obtain an average number of pixels of 6-8 images per group. 40| Use the rectangular fixed ratio style of the marquee tool to draw a box around the scale bar to obtain the number of pixels of the scale bar.
41|
To convert the number of pixels of lymphatic vessels into area per field, divide the value obtained from
Step 39 by the value obtained from
Step 40. We have used the formula lymph vascularization area (µm 2 ) = [y-pixels × [length of the scale bar (µm)
2 ]] / x-pixels (Fig. 2e) . (x-pixels = the number of pixels in the area of the square, with length of the scale bar as the length of side of the square.)  crItIcal step If fewer corneal samples are used for quantification, inaccurate experimental data might be generated because of variation of corneal lymphangiogenesis between individuals within each group.
? trouBlesHootInG Troubleshooting information can be found in table 1. 
antIcIpateD results
If this protocol is executed smoothly, the expected results should be highly reproducible and quantifiable. For example, successful surgical operation on the corneal tissue is reflected by a lack of corneal neovascularization in control groups that contain polymers without factors (Fig. 3a) . However, if corneal neovascularization occurs in a substantial proportion of the operated corneas in the control group, the angiogenic response is usually triggered by operation-induced inflammation or tissue damage. The operation-triggered nonspecific angiogenic response indicates the failure of the experimentation and the data cannot be used. Knowing that all polymer-or carrier-implanted corneas are avascular, various angiogenic factor-induced angiogenic responses can be photographed and directly compared in various groups. For example, corneal angiogenesis induced by VEGF-A, VEGF-C, platelet-derived growth factor-BB, hepatocyte growth factor, insulin-like growth factor (IGF) and FGF-2 can be directly compared (Fig. 3) . These results not only allow investigators to compare blood vessel density but also to compare the vascular structures and architectures induced by various factors. For instance, the VEGF-A-induced corneal vasculature is fundamentally different from vasculatures induced by other factors (Fig. 2) . After double immunostaining with blood and LEC-specific markers, such as a combination of CD31 and LYVE-1 (Fig. 2b ) or a combination of CD31 and VEGFR3 (Fig. 2b) , FGF-2-induced corneal new blood and lymphatic vessels are readily detected. Notably, VEGFR3 is distributed mainly on lymphatics, although weak signals can also be detected in blood vessels (Fig. 2c) . Thus, VEGFR3 cannot be used as lymphatic-specific marker. The corneal lymphatic networks usually consist of large-diameter vessels with blunted ends of vascular sprouts as compared with blood vessels (Fig. 2) . In contrast, blood vessel networks are composed of smaller microvessels at higher densities relative to lymphatics. Examples of various factor-induced lymphangiogenic vessels in the cornea after immunostaining with LYVE-1 using the whole-mount procedure, and images were captured with a confocal microscope. The dashed lines encircle the implanted pellet (P). Green color shows lymphatic vessels and red color shows blood vessels. All animal studies were approved by the animal care and use committee of the Northern Stockholm Experimental Animal Ethical Committee. coMpetInG FInancIal Interests The authors declare no competing financial interests.
